The most interesting case for the expression control analysis was that of ADCY9, a biomarker for glioma [74], lung [75], and hepatocellular carcinoma [76], as well as colorectal [77], bladder [78], and pancreatic cancers [79]. This evidence concerns the gene ADCY9 and central nervous system cancer.